

| Country Demographics <sup>1, 2, 6</sup>                 |            |
|---|------------|
| Total Population (2020) <sup>6</sup>                    | 5,073,296  |
| Urban Population (% of total, 2020) <sup>6</sup>        | 52.1%      |
| Health expenditure per capita (\$US, 2017) <sup>1</sup> | \$56.6     |
| Health expenditure, total (% of GDP, 2017) <sup>1</sup> | 8.16%      |
| Total births (2013) <sup>2</sup>                        | 152,000    |
| Surviving Infants (2013) <sup>2</sup>                   | 143,000    |
| Life expectancy at birth (years, 2020) <sup>6</sup>     | 64.7 years |
| Number of districts (2013) <sup>2</sup>                 | 15         |


| HBsAg Prevalence <sup>3</sup> |       |
|-------------------------------|-------|
| Pre-vaccine HBsAG+ (%)        | 17.2% |

| Liver Cancer as Cause of Cancer Death (in Men) <sup>4</sup> |            |
|---|------------|
| Year: 2018  | Ranking: 2 |


| 2019 Country Comparison in African Region (47 Countries) <sup>5</sup> |         |  |                                  |  |
|---|---------|--|----------------------------------|--|
|   | Liberia | Number of countries with reported coverage | Highest reported coverage in AFR | Lowest reported coverage in AFR        |
| HepB3 <sup>5</sup>  | 74%     | 47   | 99% (Seychelles)                 | 47% (Central African Republic, Guinea) |
| HepB BD <sup>5</sup>  | NR      | 7  | 99% (Algeria)                    | 9% (Cote d'Ivoire)                     |

| Hepatitis B Immunization Coverage |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |
|-----------------------------------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|
|                                   | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 |
| HepB3                             | NR   | NR   | NR   | NR   | NR   | NR   | NR   | NR   | 75%  | 81%  | 70%  | 77%  | 80%  | 80%  | 63%  | 80%  | 84%  | 84%  | 84%  | 74%  |
| HepB BD                           | NR   | NR   | NR   | NR   | NR   | NR   | NR   | NR   | NR   | NR   | NR   | NR   | NR   | NR   | NR   | NR   | NR   | NR   | NR   | NR   |
| BCG                               | 78%  | 73%  | 69%  | 64%  | 60%  | 76%  | 77%  | 77%  | 85%  | 87%  | 73%  | 85%  | 85%  | 87%  | 73%  | 74%  | 97%  | 87%  | 92%  | 84%  |
| DTP3                              | 46%  | 42%  | 39%  | 35%  | 31%  | 60%  | 60%  | 65%  | 75%  | 81%  | 70%  | 77%  | 80%  | 80%  | 63%  | 80%  | 84%  | 84%  | 84%  | 74%  |

Liberia: HepB3 vs. DTP3



Liberia: BCG



Abbreviations: NA= not applicable; NR= no report; HepB BD= birth dose within 24 hours; HepB3= at least 3 doses of HepB vaccine; HBsAG= HepB surface antigen. Data Compiled by Asian Liver Center at Stanford University 2019: World DataBank: World Development Indicators database<sup>1</sup>, WHO Immunization Summary: A statistical reference containing data through 2013<sup>2</sup>, WHO Public Health Significance, Targets, Strategies: HBV country profiles<sup>3</sup>, Global Cancer Observatory: Cancer Today-IARC<sup>4</sup>, WHO Vaccine-Preventable Diseases: Monitoring System. 2019 global summary WHO-UNICEF estimates<sup>5</sup>, CIA The World Factbook<sup>6</sup>